The 100 percent drug tariff starts on 29 September. Most of what you inject is not in it

If you have seen "100 percent tariff on drugs from 29 September" and wondered what it does to your toxin cost, the honest answer is: probably much less than the headline, and possibly nothing. The rate is not one number. It runs 0, 15, 20 or 100 percent depending on who made the product and where. AbbVie, which owns Botox Cosmetic and Juvederm, is one of thirteen companies the order names as already holding an agreement with Washington, and for that group the order sets the rate at zero until January 2029. Fillers are not drugs at all, so this measure does not reach them, though a separate tariff already has. Below is how to work out your own number in about ten minutes, and the invoice line you should refuse to pay.

What actually happens on Tuesday week

At 12:01 in the morning on 29 September 2026, US Customs starts collecting a new duty on imported patented medicines. It comes from Proclamation 11020, signed on 2 April 2026 under section 232 of the Trade Expansion Act, the same national security power behind the steel and aluminium tariffs.

This is not the start of the programme. Seventeen named companies, listed in Annex III of the order, have been inside it since 31 July 2026. Tuesday is when everybody else joins.

The number in every headline is 100 percent. That is the base rate, and it is genuine. It is also the rate that the fewest products actually pay.

The rate is a ladder, not a number

Read this list once and you will know more than most of the people who will email you about it this week. All of it is in clause 3 of the order.

• 100 percent on patented pharmaceuticals and their active ingredients, as the default.
• 15 percent if the product is a product of the European Union, Japan, South Korea, Switzerland or Liechtenstein.
• Zero if it is a product of the United Kingdom. The order set the UK at 10 percent, then Commerce published a notice on 4 August cutting it to zero, backdated to 31 July, because the US and UK concluded a pharmaceutical pricing arrangement.
• 20 percent for a company with an onshoring plan approved by the Commerce Secretary. That rate becomes 100 percent on 2 April 2030.
• Zero until 20 January 2029 for a company that has both the onshoring plan and a Most-Favored-Nation pricing agreement with Health and Human Services.

And three carve-outs that matter more than any of the rates:

• Generic drugs and biosimilars are out. The order says they are not subject to section 232 tariffs "at this time".
• US-origin pharmaceutical products are out, also "at this time".
• Only listed goods are in. The order works off a fixed list of tariff codes. A product whose code is not on that list is not covered, whatever it is made of.

Five questions that decide your invoice

Work down these in order. The first "no" ends the enquiry.

1. Is it a drug, or a device? This measure covers pharmaceuticals. The FDA regulates dermal fillers as "medical device implants", not as drugs, so hyaluronic acid fillers, threads and the kit you buy alongside them are not in this action at all. Keep reading anyway, because being outside this tariff is not the same as being outside every tariff.

2. Is it generic, or a biosimilar? Lidocaine, saline, most of your pharmacy shelf. Out, for now.

3. Is it made in the United States? Out, for now.

4. Whose product is it? Thirteen companies are named in Annex II as already having signed a company-specific agreement with the Commerce Secretary. AbbVie Inc., dated 20 March 2026, is one of them, and Allergan Aesthetics, which sells Botox Cosmetic and the Juvederm collection, is an AbbVie company. The order says the zero rate "shall also apply per the terms of the agreements listed in Annex II". Note the wording. The terms of those agreements are not public, so what the order guarantees you is the framework, not the invoice.

5. What country is the product of? If you get here, the answer is 15 percent for the EU, Japan, South Korea, Switzerland and Liechtenstein, zero for the UK, and 100 percent for anywhere else.

One honest gap in this list. Whether a specific product is a "patented pharmaceutical article" turns on a two-part test in the order: it must be under a valid, unexpired US patent and listed in the FDA's Orange Book for drugs or Purple Book for biologics. Your distributor knows the answer. You cannot work it out from the box.

Why 15 percent on the tariff is not 15 percent on your bill

This is the part that will cost people money, so slow down here.

A duty is charged on the customs value of the goods at the border. That is roughly what the importer paid for them. It is not what you pay. By the time a vial reaches your treatment room it carries the manufacturer's margin, the distributor's margin, freight, cold chain and handling.

Take a product that enters the country at a customs value of $100 and reaches you at $400. Those are illustrative figures, not a benchmark, so put your own in. A 15 percent duty is $15. As a share of your $400 buying price, that is 3.75 percent, not 15. At the full 100 percent rate the duty is $100, which is 25 percent of your price, not a doubling.

So when a supplier applies a flat percentage "tariff surcharge" to your whole invoice, they are not passing through a cost. They are marking up their own margin as well, and using the tariff as the reason.

There is one more thing in the order worth knowing: drawback is available. If duty-paid goods are later exported, the importer can reclaim the duty. That is not your claim, but it is a useful thing to know when someone tells you a cost is unavoidable.

One manufacturer has already said the quiet part in a filing

You do not have to take my word for how the industry is handling this. Evolus, which sells the Jeuveau toxin and the Evolysse filler line, described its position in its quarterly report to the Securities and Exchange Commission for the period ended 30 June 2026.

On the toxin: "beginning September 29, 2026, Jeuveau, a biologic that is manufactured in South Korea, could be subject to a 15% tariff under Section 232 of the Trade Expansion Act of 1962, depending on how the applicable rules are interpreted and applied." The company adds that it has increased inventory purchases in advance of the potential tariff.

On the filler: Evolysse, which it imports from the European Union, carried a temporary 10 percent tariff in the second quarter, and from 24 July 2026 that was replaced by a new 10 percent tariff under section 301 of the Trade Act of 1974.

Two lessons in one filing. First, "could be subject to, depending on how the rules are interpreted" is where a large, well-advised company sits eight weeks out, which tells you how much certainty to expect from a rep on the phone. Second, your fillers being outside the pharmaceutical tariff does not mean they are outside tariffs.

The dates that matter more than Tuesday

• 12 June 2026. Commerce asked for onshoring applications within 30 days of its 13 May notice. Whoever is in, is in. Your supplier's rate for the next few years was largely settled in the spring.
• 2 April 2027. The Secretary must report to the President within a year on whether to act on generics as well. Most of what a clinic buys by volume is generic. This is the date that could turn a narrow measure into a broad one.
• 20 January 2029. The zero rate for companies with MFN pricing agreements ends.
• 2 April 2030. The 20 percent onshoring rate becomes 100 percent.

If you are modelling product cost past 2028, the tariff line is not flat.

What a buyer sees when one brand is your whole cost line

Here is the bit that outlasts the news cycle.

A clinic's product cost is usually concentrated in a very small number of SKUs from a very small number of manufacturers. That concentration is invisible while prices are stable and obvious the moment a policy like this lands. An acquirer looking at your gross margin does not just ask what it was. They ask what happens to it if one supplier moves price by a fifth, and whether you have ever proved you can hold margin when that happens.

If your answer is "we would put our prices up", the follow-up is: when did you last do that, and what happened to bookings? A clinic that has repriced deliberately and kept its clients has demonstrable pricing power. A clinic that has never tested it is carrying an unpriced risk into the valuation conversation, and buyers discount what they cannot measure.

There is also a client-side version of the same concentration. If every treatment in your book depends on one branded product, you have the supplier's risk and the brand's risk at once. The clinics that come out of this well will be the ones whose clients book them, not a brand name on a box.